Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial

被引：0

作者：

Ahn, M. -J. ^{[1
]}

Delmonte, A. ^{[2
]}

Ghosh, S. ^{[3
]}

Hochmair, M. ^{[4
,5
]}

Yang, T. -Y. ^{[6
]}

Yang, J. C. -H. ^{[7
,8
]}

Han, J. -Y. ^{[9
]}

Hansen, K. Holmskov ^{[10
]}

Wu, Y. ^{[11
]}

Wan, Y. ^{[11
]}

Lin, H. M. ^{[11
]}

Kretz, J. ^{[12
]}

Hupf, B. ^{[11
]}

Kurec, A. M. ^{[13
]}

Churchill, E. N. ^{[14
]}

Fram, R. J. ^{[11
]}

Cabasag, C. J. ^{[15
]}

Goriya, V. ^{[16
]}

Zhao, Y. ^{[17
]}

Gemmen, E. ^{[18
]}

Campelo, M. R. Garcia ^{[19
,20
]}

机构：

[1] Sungkyunkwan Univ, Dept Med Oncol, Samsung Med Ctr, Div Hematol,Sch Med, Seoul, South Korea

[2] IRCCS Ist Romagnolo Studio Tumori Dino Amadori I, Cesena, Italy

[3] Guys & St Thomas NHS Fdn Trust, London, England

[4] Klin Floridsdorf, Dept Resp & Crit Care Med, Vienna, Austria

[5] Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria

[6] Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan

[7] Natl Taiwan Univ Hosp, Taipei, Taiwan

[8] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan

[9] Natl Canc Ctr, Goyang, South Korea

[10] Odense Univ Hosp, Odense, Denmark

[11] Takeda Dev Ctr Amer Inc, Lexington, MA USA

[12] Takeda Pharmaceut Int AG, Glattpark Opfikon Zurich, Zurich, Switzerland

[13] Takeda Pharmaceut Int Singapore Emerging Markets, Singapore, Singapore

[14] Takeda Pharmaceut USA Inc, Lexington, MA USA

[15] IQVIA RDS France, Courbevoie, France

[16] IQVIA RDS France, Courbevoie, France

[17] IQVIA RDS Shanghai Co Ltd, Shanghai, Peoples R China

[18] IQVIA Falls Church, Falls Church, VA USA

[19] Univ Hosp Coruna, Dept Med Oncol, La Coruna, Spain

[20] Biomed Res Inst INIBIC A Coruna, La Coruna, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

Brigatinib; ALK plus NSCLC; ALK TKI;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.12B.03

引用

页码：S200 / S200

页数：1

共 50 条

[41] ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive, advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
Popat, S.
Tiseo, M.
Gettinger, S.
Peters, S.
Haney, J.
Kerstein, D.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2016, 27
[42] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
Ahn, M.
Camidge, D. R.
Tiseo, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1755 - S1756
[43] Real-World Outcomes in Patients with EGFR/ALK-Positive NSCLC Treated with Chemotherapy Following 1 or 2 Lines of TKI Therapy
Cheema, P.
Ton, T.
Lambert, P.
Merritt, D.
Morris, S.
Shankar, G.
Ganti, A. K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S46 - S46
[44] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
Camidge, D. Ross
Tiseo, Marcello
Ahn, Myung-Ju
Reckamp, Karen
Hansen, Karin
Kim, Sang-We
Huber, Rudolf
West, Howard
Groen, Harry
Hochmair, Maximilian
Leighl, Natasha
Gettinger, Scott
Langer, Corey
Paz-Ares, Luis
Smit, Egbert
Kim, Edward
Reichmann, William
Clackson, Tim
Kerstein, David
Haluska, Frank
Kim, Dong-Wan
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1169
[45] Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC
Hochmair, M.
Ahn, M-J
Camidge, D. R.
Tiseo, M.
Reckamp, K.
Hansen, Holmskov K.
Kim, S-W
Huber, R.
West, H.
Groen, H.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares Rodriguez, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D-W
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 271 - 271
[46] Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK plus NSCLC
Arnaoutakis, Konstantinos
Wan, Yin
Elliott, Jennifer
Young, Matt
Yin, Yu
Leventakos, Konstantinos
Lin, Huamao M.
Dimou, Anastasios
ADVANCES IN THERAPY, 2024, 41 (08) : 3217 - 3231
[47] Ceritinib Dosing Patterns and Outcomes of Patients with ALK plus NSCLC in a Real-World Practice in the United States
Bendaly, Edmond
Dalal, Anand
Culver, Kenneth
Galebach, Philip J.
Bocharova, Iryna
Foster, Rebekah
Struebbe, Gero
Guerin, Annie
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S314 - S315
[48] Real-World Comparative Effectiveness in Advanced NSCLC and High PD-L1 with 1L Immune Checkpoint Inhibitors ± Chemotherapy
Hsu, M. L.
Xia, Q.
Aggarwal, S.
Nkhoma, E.
R, D.
Hager, T.
Quek, R.
Feliciano, J.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S598 - S598
[49] Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy
Julian, C.
Machado, R.
Girish, S.
Chanu, P.
Heinzmann, D.
Harbron, C.
Gershon, A.
Pfeiffer, S.
Zou, W.
Quarmby, V.
Zhang, Q.
Chen, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S644 - S644
[50] Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results
Gettinger, Scott N.
Bazhenova, Lyudmila
Salgia, Ravi
Langer, Corey J.
Gold, Kathryn A.
Rosell, Rafael
Shaw, Alice
Weiss, Glen J.
Dorer, David J.
Rivera, Victor M.
Conlan, Maureen G.
Kerstein, David
Camidge, Ross
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S238 - S239

← 1 2 3 4 5 →